Regeneron (REGN) Tops Q2 EPS by 104c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron Reports Second Quarter 2017 Financial and Operating Results
August 3, 2017 6:30 AM EDTTARRYTOWN, N.Y., Aug. 3, 2017 /PRNewswire/ -- Â
Second quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 11% to $919 million versus second quarter 2016 Second quarter 2017 EYLEA global net sales(1) increased 11% to $1.46 billion versus second quarter 2016 Raised estimated full year 2017 EYLEA U.S. net sales growth guidance to approximately 10% over 2016 Kevzara® (sarilumab) approved by FDA and European Commission for adults with moderately to severely active rheumatoid arthritisRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2017 and provided a business... More
